Smith Stan's Form 4 filing
MAIA Biotechnology, Inc. (MAIA) · filed Jan 12, 2026
- Accession no.
- 0001878313-26-000021
- Filed
- Jan 12, 2026
- Trade date
- Sep 19, 2022-May 1, 2024
- Filing delay
- 1,211 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $9.96K. It was filed 1211 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Smith StanCIK 0001913199 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2022 | Common Stock | PPurchaseAcquired | +2,700 | $3.69 | +$9,963 | 1,424,178 | Indirect | |
| May 1, 2024 | Common Stock | GGiftAcquired | +20,000 | $0.00 | $0 | 1,444,178 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.